Viatris Investor Event Summary Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Date**: March 19, 2026 - **Key Leadership**: CEO Scott Smith, CFO Doretta Mistras, Chief R&D Officer Philippe Martin, Chief Commercial Officer Corinne Le Goff, Chief Strategy Officer Hemanth J. Varghese Core Business Segments - Viatris operates three main business segments: - **Global Generics**: A strong generics powerhouse - **Established Brands**: Includes iconic brands like Lipitor, Norvasc, Celebrex, Xanax, and Viagra - **Innovative Medicines**: A growing segment focusing on new drug development [6][5][4] Financial Performance and Projections - **2026 Revenue**: Expected to generate approximately $14.7 billion - **Adjusted EBITDA**: Projected at $4.3 billion - **EPS**: Anticipated at $2.40 per share - **Free Cash Flow**: Expected to be around $2.2 billion - **Long-term Targets (by 2030)**: - Total revenue growth: 5%-6% - Adjusted EBITDA growth: 7%-8% - Adjusted EPS growth: 9%-10% - Annual free cash flow: More than $3 billion [6][10][9] Strategic Initiatives - Focus on: - Driving base business growth - Fueling innovative portfolio development - Modernizing for sustainable growth - Plans to generate at least $11 billion in cash by 2030, balancing shareholder returns and business development [7][8][9] R&D and Pipeline Development - R&D focuses on three areas: - **Generic Medicines**: Core and complex generics - **Value-Added Medicines**: Established brands and 505(b)(2) applications - **Innovative Portfolio**: Emerging assets like Selatogrel and Cenerimod [15][16][22] Key Pipeline Assets - **Selatogrel**: A P2Y12 inhibitor for self-administered emergency treatment of recurrent myocardial infarction (MI). Expected to initiate a global registration study (SOS-MI) [26][27][30]. - **Cenerimod**: An oral S1P1 receptor modulator for systemic lupus erythematosus (SLE) and lupus nephritis. A pivotal program (OPUS) is underway with results anticipated in the first half of 2027 [31][32][36]. Commercial Strategy - Viatris has a robust commercial platform with a sales force of approximately 8,500 people, targeting growth across 165 countries [50][51]. - **Growth Drivers**: - **Europe**: Continued growth from promoted brands and generics leadership - **North America**: Leadership in complex generics and expansion of promoted brands - **Emerging Markets**: Focus on established brands leveraging physician trust [52][53][54] Upcoming Product Launches - **Fast-Acting Meloxicam**: A non-opioid option for acute pain, with peak net sales potential of up to $500 million [60][61]. - **Low-Dose Estrogen Contraceptive Patch**: Expected peak net sales of $180 million or higher, targeting young women [62][63]. - **Cenerimod and Selatogrel**: Anticipated global launches with blockbuster potential, with Cenerimod projected to exceed $1 billion in peak sales [65][68]. Conclusion - Viatris is positioned for durable growth through a diversified portfolio of generics, established brands, and innovative medicines. The company is focused on executing its strategic initiatives and leveraging its strong R&D capabilities to drive future success [69][70].

Investor Event Our Path to Sustained Revenue and Earnings Growth Through 2030 March 19, 2026 Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about: 2026 financial guidance; long-term financial targets; base case long-term target CAGR of 3-4% for Total Revenues, 4-5% for Adjuste ...

Core Viewpoint - Viatris Inc. aims to outline its strategic vision and financial framework to achieve sustained revenue and earnings growth through 2030, emphasizing a diversified portfolio and strong cash flow generation [1][2][3]. Long-Term Financial Targets - The company expects a compound annual growth rate (CAGR) of 5% to 6% for total revenues, 7% to 8% for adjusted EBITDA, and 9% to 10% for adjusted EPS through 2030, with more than $3 billion in annual free cash flow anticipated by that year [4][10][18]. - For its base case long-term targets, Viatris anticipates a total revenue CAGR of 3% to 4%, adjusted EBITDA CAGR of 4% to 5%, and adjusted EPS CAGR of 6% to 7% [7][9][18]. Financial Flexibility and Cash Deployment - The company projects to have over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to disciplined accretive business development [9][15]. - Viatris identified around $650 million in gross cost savings over three years, with up to $250 million expected to be reinvested in the company [8][15]. Growth Drivers - Key growth drivers include impactful near-term product launches such as fast-acting meloxicam and low-dose estrogen weekly patch in the U.S., as well as selatogrel and cenerimod [4][8][18]. - The company’s diversified portfolio and strong cash flow generation provide significant financial flexibility to invest in growth while maintaining a disciplined capital allocation framework [2][5][15]. Strategic Vision and Priorities - The company emphasizes a strategic vision focused on evolving its base business into a more durable portfolio of higher-margin generics, value-added medicines, and established brands [4][5][15]. - The investor event will highlight the company's commercial capabilities, R&D pipeline, and overall strategic priorities to support long-term growth [5][15].

Investor company presentation February 2026 Forward-looking statements The information in this presentation contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "intend", "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements ...

Summary of Idorsia's Conference Call Company Overview - **Company**: Idorsia - **CEO**: Dr. Srishti Gupta - **Key Products**: Quvivic (daridorexant) and Tryvio (Jeraygo) - **Industry**: Healthcare, specifically pharmaceuticals focusing on insomnia and hypertension Core Points and Arguments 1. Strategic Focus - Idorsia is executing a balanced strategy to commercialize two assets and advance its pipeline in a disciplined manner, aiming to create value for patients and shareholders [2][3] 2. Product Highlights - **Quvivic (daridorexant)**: - A dual orexin receptor antagonist aimed at changing the standard of care for insomnia [3] - Addresses both nighttime and daytime functioning, with a focus on improving productivity and public health [5][6] - Significant global GDP loss of over $400 billion annually due to insomnia-related issues [5] - Unique in demonstrating improvement in daytime functioning, which is not claimed by existing insomnia treatments [6][8] - Global brand presence with increasing adoption in markets like Japan and Europe, with over 100,000 patients in China within months of launch [9][10] - **Tryvio (Jeraygo)**: - First approved antihypertensive therapy targeting the endothelin system, addressing uncontrolled hypertension [16][17] - Aimed at a significant market with 1.4 billion people affected by hypertension globally, with 26 million in the U.S. alone not adequately controlled [16] - Unique mechanism of action allows for safe addition to existing therapies without increased risk of hyperkalemia [19][21] 3. Market Potential - Quvivic has blockbuster potential with U.S. exclusivity until at least 2036, and a focus on pediatric insomnia, which is an unmet need affecting 10%-30% of children in the U.S. [13][14] - Tryvio has a projected peak year sales potential of $5 billion, targeting 8-13 million patients not well controlled [20] 4. Pipeline Development - Idorsia has multiple late-stage assets, including: - **Selatogrel** for acute myocardial infarction in partnership with Viatris [23] - **Cenerimod** for systemic lupus and lupus nephritis, with phase 3 interim results expected soon [24] - **Lucerostat** for Fabry's disease, with a market potential of $4 billion [25] 5. Financial Position - Idorsia has a cash runway into 2028, with liquidity of approximately $258 million and projected revenue of $262 million from Quvivic sales in 2026 [27] 6. Future Focus Areas - Continued support for Quvivic sales and new distribution models, including potential U.S. descheduling [28] - Expansion of partnerships for Tryvio and Jeraygo, and advancing the lucerostat registration [28][29] Additional Important Content - The company is addressing the public health crisis of inappropriate benzodiazepine use in insomnia treatment [5][8] - The unique design of Quvivic allows for improved sleep duration and quality without carryover effects, enhancing daytime alertness [41][42] - The synthetic glycan vaccine platform is being developed for Clostridium difficile and other bacterial infections, showcasing Idorsia's innovative approach beyond traditional pharmaceuticals [43][44][45] This summary encapsulates the key points discussed during the conference call, highlighting Idorsia's strategic direction, product offerings, market potential, and future initiatives.

Two products with blockbuster potential and a pipeline of first- or best-in-class drugs J. P. Morgan Healthcare Conference 2026 – January 2026 Forward-looking statements The information in this presentation contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "intend", "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "antici ...

Summary of Viatris Conference Call Company Overview - Viatris operates as three distinct businesses: a global generics company, an established brands company, and an emerging innovative brands platform [2][3] - The company reported $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in free cash flow over the last 12 months [2] Key Financial Highlights - Viatris delivered $14.1 billion in revenue and $4.1 billion in EBITDA [2] - Achieved $2.32 in adjusted EBITDA and $2.2 billion in free cash flow [2] - The company operates in 165 countries with 1,400 unique products, serving over 1 billion people annually [3] Strategic Developments - The company advanced its pipeline with five positive phase 3 readouts out of six [4] - Significant progress was made with Cenerimod, Selatogrel, and Lucerastat in their phase 3 programs [4] - Over $1 billion was returned to shareholders through dividends and share buybacks [4] - Conducted 60 regional business development deals to support the base business, particularly in Japan [4][5] Future Outlook - Anticipated high-value product launches in 2026, including Sotagliflozin, Phentolamine, and Effexor GAD [6][7] - The company expects to generate significant cash flow in 2026, with plans for continued shareholder returns and growth asset development [9] - A strategic review is expected to yield substantial savings and reinvestment opportunities [22][24] Market Dynamics - The company is focusing on the U.S. market for high-margin revenue-generating assets, while also revitalizing its portfolio in Japan [36] - The competitive landscape is favorable for acquiring assets in the $500 million-$1 billion revenue range, with less competition for these assets [20][21] Pipeline and Product Development - Positive phase 3 results for Cenerimod and Selatogrel are expected to lead to significant market opportunities [51][60] - Fast-Acting Meloxicam is positioned to address the opioid crisis in pain management, with a strong market potential [43][45] - Selatogrel aims to revolutionize acute myocardial infarction management, with a large patient population and significant unmet need [60][62] Challenges and Risks - Pricing pressures and policy adjustments are anticipated in the JANS business, along with generic competition in Japan [29] - The Indore facility's remediation is nearing completion, with limited expected volatility in 2026 numbers [30][32] Capital Allocation Strategy - The company plans a balanced approach to capital allocation, focusing on shareholder returns and business development [34] - Expected free cash flow of over $2 billion annually for the next five years [33] Conclusion - Viatris is positioned for sustainable growth with a strong pipeline, strategic acquisitions, and a focus on enhancing its core business while navigating market challenges [12][15]

Summary of Viatris Conference Call Company Overview - **Company**: Viatris - **Business Segments**: - Global generics footprint (originating from Mylan) - Established products (notable brands include Lipitor, Norvasc, Xanax, Viagra, Celebrex from Upjohn acquisition) - Growing innovative segment [2][3] Core Points and Arguments - **Strategic Review**: Viatris is undergoing an enterprise-wide strategic review to assess its structure and cost efficiency, aiming for sustainable revenue and earnings growth beyond 2026 [4][20] - **Financial Performance**: - The company has returned over $1 billion to shareholders through dividends and share repurchases this year [3] - Anticipates approximately $500 million in new revenues annually from the base business, with a net growth of around $200 million after accounting for losses and price declines [8] - Internal expectations for revenue growth are higher than market estimates, with a goal to achieve continuous earnings growth over the next three to five years [7][26] - **Operating Leverage**: The company aims to improve operating leverage, targeting a growth profile shift from 1% to 3-5% [9][10] Pipeline and Product Development - **Innovative Assets**: Viatris is focusing on developing innovative products, including fast-acting meloxicam, which shows a faster onset of action compared to competitors [38][39] - **CNS Assets in Japan**: The acquisition of Aculys added CNS assets to Viatris' portfolio, with a strategic focus on growing revenues in the challenging Japanese market [32][34] - **Upcoming Launches**: The company is preparing for the launch of several products, including meloxicam and antiplatelet drugs, with significant market potential [46][63] Market Dynamics and Challenges - **External Challenges**: The company has faced external challenges such as tariffs, policy changes, and FDA regulations, which have impacted operations [2][3] - **Cost Structure Review**: Viatris is reviewing its cost structure post-merger and divestitures, aiming for significant cost savings while ensuring that these savings are sustainable [20][21] Investment and Capital Allocation - **Capital Deployment**: Viatris generates approximately $2 billion in free cash flow annually, with plans to allocate capital evenly between shareholder returns and business development [28][29] - **Focus on High-Margin Assets**: The company is looking to acquire high-margin, revenue-generating assets, particularly in the U.S. and Japan [35] Other Important Insights - **Market Positioning**: Viatris is positioning its innovative products as differentiated solutions in the market, with a focus on addressing unmet medical needs [39][63] - **Long-Term Vision**: The management emphasizes a long-term vision for growth, with a commitment to maintaining a strong base business while investing in innovation [6][26] This summary encapsulates the key points discussed during the Viatris conference call, highlighting the company's strategic direction, financial performance, product pipeline, and market challenges.

Summary of Conference Call Company Overview - The conference was held at the Piper Sandler Healthcare Conference featuring Doretta Mistras (CFO) and Philippe Martin (Chief R&D Officer) of the company [1][2] Capital Deployment Strategy - The company maintains a balanced capital allocation philosophy, aiming for a 50/50 split between capital deployment and capital return over a three to five-year period [2] - In the current year, the focus has been on capital returns, particularly share buybacks, due to operational circumstances and stock price considerations [2] - The company is actively pursuing innovative, branded, patent-protected assets to enhance near-term revenue and EBITDA growth, particularly in the US [3] R&D Focus - The current strategy emphasizes commercial-stage assets, with a focus on late-stage products like Cenerimod and Selatogrel [5] - Cenerimod is undergoing two large Phase III studies for systemic lupus erythematosus (SLE), with OPUS-2 fully enrolled and OPUS-1 expected to follow shortly [7] - The drug is positioned to be used alongside standard treatments without adding safety concerns, targeting a significant unmet need in SLE and lupus nephritis [8][15] Clinical Trials and Market Positioning - The Phase III trials for Cenerimod are designed to account for previous learnings, particularly focusing on patients with high interferon I levels, which showed the greatest treatment effect [9] - The company is optimistic about the potential of Cenerimod in lupus nephritis, having received positive feedback from regulatory bodies [11][12] - Selatogrel's Phase III global program for acute myocardial infarction is progressing well, with nearly 1,000 patients enrolled per month and full enrollment expected by the end of the year [16] Fast-Acting Meloxicam Product - The company is preparing for a pre-NDA meeting with the FDA to discuss filing and potential for accelerated review [20] - The fast-acting meloxicam product targets over 80 million acute pain cases annually, with a focus on outpatient and ambulatory surgical centers [22] - The product aims to provide a non-opioid alternative in a market where over 50% of acute pain cases still rely on opioids [22] Market Differentiation and Pricing Strategy - The company is exploring pricing strategies and market access for the fast-acting meloxicam, aiming for a balance between value proposition and broad patient access [24] - The product is expected to have a minimum of three years of exclusivity through the 505(b)(2) pathway, with ongoing efforts to extend this exclusivity [28] Presbyopia Opportunity - The company sees a significant market opportunity in presbyopia, with over 90% of adults over 45 affected, and aims to differentiate its product through a unique mechanism of action that avoids common side effects associated with other treatments [30][32] Enterprise-Wide Strategic Review - An enterprise-wide strategic review is underway to enhance long-term sustainable revenue and EBITDA growth, focusing on various operational aspects including R&D, manufacturing, and commercial infrastructure [34] Conclusion - The company is strategically positioned to leverage its R&D pipeline and capital deployment strategy to drive growth and address unmet medical needs across various therapeutic areas [34]